INMB

$1.28

Post-MarketAs of Mar 17, 8:00 PM UTC

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.28
Potential Upside
5%
Whystock Fair Value$1.34
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic ma...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$34.03M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.85
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-155.77%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.11

Recent News

TipRanks
Feb 11, 2026

INmune Bio submits pre-submission package for CORDStrom with MHRA

INmune Bio (INMB) has formally submitted its pre-submission package for CORDStrom with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency. This early engagement step is designed to solicit targeted scientific, regulatory, and procedural feedback, streamlining the full Marketing Authorization Application process and potentially shortening time to market for what could become the first systemic therapy for this devastating “butterfly skin” disease. INmune Bio has completed th

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Nov 6, 2025

INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Oct 31, 2025

INmune Bio Inc (INMB) Q3 2025 Earnings Call Highlights: Regulatory Progress and Financial ...

INmune Bio Inc (INMB) reports significant advancements in drug trials and financial health, while navigating regulatory delays and competitive pressures.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Sep 8, 2025

INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

INmune Bio (INMB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Aug 10, 2025

Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans?

NasdaqCM:INMB 1 Year Share Price vs Fair Value Explore INmune Bio's Fair Values from the Community and select yours...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.